98%
921
2 minutes
20
This manuscript provides an outlook on using cognitive enhancers and their ethical implications. Cognitive enhancers, including prescription medications like modafinil and methylphenidate, over-the-counter supplements such as ginseng and caffeine, and novel nootropic agents like gene therapy and stem cell interventions, improve cognitive functions such as memory, focus, and learning. While they have shown efficacy in treating neurodegenerative disorders like Alzheimer's disease and attention-deficit/hyperactivity disorder (ADHD), their growing use by healthy individuals raises ethical concerns. This paper addresses the benefits of cognitive enhancers, such as improved academic and professional performance, and the associated risks, including addiction, dependence, and long-term health consequences. It also delves into social and ethical issues, including disparities in access, fairness, coercion in competitive environments, and distinguishing between genuine and substance-enhanced achievements. Additionally, the paper examines current regulations and proposes stronger legal frameworks to address the increasing use of cognitive enhancers. In conclusion, while cognitive enhancers have potential therapeutic benefits, a balanced approach is needed to regulate their use and ensure they are not misused to gain unfair advantages, particularly in non-medical settings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333774 | PMC |
http://dx.doi.org/10.1097/MS9.0000000000003442 | DOI Listing |
Clin Lab
September 2025
Background: Patients with epilepsy often require long-term antiepileptic medications, which can affect hematological parameters. Influenza (H1N1) infection is known to potentially cause thrombocytopenia. This case examines the clinical implications of a 29-year-old female patient with epilepsy who developed influenza and significant platelet reduction.
View Article and Find Full Text PDFClin Nucl Med
October 2025
Department of Nuclear Medicine, Centre Georges François Leclerc, Dijon, France.
Parathyroid carcinoma (PC) is a rare disease, with a frequency of 0.005% of all malignancies. Approximately 30% of patients will develop metastases at some point in the disease.
View Article and Find Full Text PDFFront Neurol
August 2025
Department of Neurology, Hyoja Geriatric Hospital, Kuseong-myeon, Yongin-si, Gyeonggi-do, Republic of Korea.
Background: Mild cognitive impairment (MCI) with amyloid PET positivity represents a prodromal stage of Alzheimer's disease (AD), yet no disease-modifying therapies are currently approved. , traditionally used in East Asian and European ethnomedicine as an oral decoction or standardized extract to support memory and cognitive function, is commonly utilized, however, its efficacy as monotherapy in biomarker-confirmed MCI remains uncertain. Aβ oligomers, produced by abnormal cleavage of amyloid precursor protein, disrupt synaptic function and contribute to cognitive decline.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
September 2025
Department of Structural Biology, University of Pittsburgh, Pittsburgh, PA 15213.
Brivaracetam (BRV) and levetiracetam (LEV) are antiseizure medications (ASMs); UCB-J is a PET tracer targeting synaptic vesicle protein 2A (SV2A); UCB7361 is closely related to padsevonil, an experimental anticonvulsant; while UCB1244283 acts as an allosteric modulator for BRV and LEV binding but not for these other ligands. The SV2A-BRV-UCB1244283 structure reveals how UCB1244283 allosterically enhances BRV binding by occupying an allosteric site near the primary binding site, preventing BRV dissociation. This allosteric site, formed by hydrophobic and uncharged residues, is an uncharacterized small-molecule binding site in SV2A.
View Article and Find Full Text PDFJ Mol Model
September 2025
Department of Chemical Engineering, Sri Sivasubramaniya Nadar College of Engineering, Rajiv Gandhi Salai (OMR), Kalavakkam, Chennai, Tamil Nadu, 603110, India.
Context: The drug solubilization is still a significant challenge in pharmaceutical research. This study examined the sigma-surface, sigma-profile, and sigma potential of 35 water insoluble drugs using deep eutectic solvents (DES) made up of a strong hydrogen bond acceptor (HBA) choline chloride (ChCl) and several hydrogen bond donors (HBDs) at the molecular level. The combinations of ChCl and 75 HBDs include acid (C1-C10), alcohol (C1-C10), aldehyde (C1-C10), amide (C1-C10), amine (C1-C10), ester (C2-C10), ether (C2-C10), and ketone (C3-C10).
View Article and Find Full Text PDF